RepliCel Life Sciences Inc. is a regenerative medicine company focused on developing autologous cell therapies that treat functional cellular deficits. The Company's product pipeline includes RCT-01-Tendon Repair, RCS-01-Skin Rejuvenation, RCH-01-Hair Regeneration and RCI-02-Dermal Injector. RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle sheath to treat chronic tendinosis caused by acute and chronic tensile overuse. RCH-01 also utilizes dermal sheath cup cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to control intradermal (dermis), subcutaneous (fat) or intramuscular injections. It is designed to support the injection of RCH-01 and RCS-01 cell therapy products. The injector has applications for dermatological procedures requiring injections of specific volumes of material at specific depths, including cellular products, fillers and collagen injections.